

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Disposition Summary					
Animals Initially In Study	50	50	50	50	50
Early Deaths					
Dosing Accident		1			
Moribund Sacrifice	3		4	4	
Natural Death	7	7	5	9	36
Survivors					
Natural Death					1
Terminal Sacrifice	40	42	41	37	13
Animals Examined Microscopically	50	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)	(50)
Inflammation, Acute		1 (2%)			
Ulcer		1 (2%)			
Submucosa, Edema		1 (2%)			
Intestine Small, Duodenum	(48)	(46)	(50)	(46)	(48)
Ulcer				1 (2%)	
Intestine Small, Ileum	(50)	(48)	(48)	(47)	(49)
Epithelium, Hyperplasia		1 (2%)			
Intestine Small, Jejunum	(48)	(46)	(49)	(46)	(43)
Inflammation, Chronic Active				1 (2%)	
Liver	(50)	(50)	(50)	(50)	(50)
Basophilic Focus	2 (4%)	1 (2%)		5 (10%)	2 (4%)
Clear Cell Focus	17 (34%)	14 (28%)	13 (26%)	21 (42%)	6 (12%)
Cyst		1 (2%)			
Eosinophilic Focus	2 (4%)	5 (10%)	5 (10%)	5 (10%)	
Eosinophilic Focus, Multiple			1 (2%)		
Hematopoietic Cell Proliferation	1 (2%)			1 (2%)	
Hemorrhage				1 (2%)	
Inflammation, Chronic					1 (2%)
Inflammation, Chronic Active	2 (4%)	1 (2%)	3 (6%)	3 (6%)	1 (2%)
Mixed Cell Focus	12 (24%)	7 (14%)	11 (22%)	7 (14%)	3 (6%)
Necrosis, Focal	4 (8%)		5 (10%)	3 (6%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Necrosis, Diffuse	1 (2%)			1 (2%)	1 (2%)
Tension Lipidosis			1 (2%)		
Centrilobular, Necrosis		2 (4%)	1 (2%)		
Hepatocyte, Hypertrophy					1 (2%)
Hepatocyte, Vacuolization Cytoplasmic	23 (46%)	13 (26%)	20 (40%)	17 (34%)	5 (10%)
Kupffer Cell, Hyperplasia			1 (2%)		
Kupffer Cell, Pigmentation				1 (2%)	
Mesentery	(4)	(4)	(3)	(7)	(3)
Fat, Necrosis	3 (75%)	3 (75%)	2 (67%)	6 (86%)	3 (100%)
Pancreas	(50)	(50)	(50)	(50)	(50)
Atrophy		3 (6%)	1 (2%)	2 (4%)	1 (2%)
Basophilic Focus			2 (4%)		
Acinus, Cytoplasmic Alteration	2 (4%)	6 (12%)	3 (6%)	1 (2%)	
Acinus, Hyperplasia, Focal	1 (2%)		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte	3 (6%)	10 (20%)	4 (8%)	3 (6%)	1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(50)	(50)
Diverticulum		1 (2%)			
Inflammation, Chronic	4 (8%)	5 (10%)	3 (6%)	3 (6%)	2 (4%)
Ulcer	1 (2%)	1 (2%)			
Epithelium, Hyperplasia	7 (14%)	7 (14%)	8 (16%)	3 (6%)	5 (10%)
Stomach, Glandular	(50)	(50)	(50)	(49)	(50)
Cyst	1 (2%)	3 (6%)	1 (2%)		
Erosion	2 (4%)	1 (2%)	1 (2%)	1 (2%)	
Epithelium, Hyperplasia	1 (2%)		1 (2%)		1 (2%)
Epithelium, Metaplasia, Squamous				1 (2%)	
Tongue	(1)	(0)	(0)	(1)	(0)

CARDIOVASCULAR SYSTEM

Heart	(50)	(50)	(50)	(50)	(50)
Cardiomyopathy		2 (4%)		1 (2%)	
Inflammation, Chronic Active				1 (2%)	
Mineralization	1 (2%)				
Thrombosis	1 (2%)				

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	(50)
Accessory Adrenal Cortical Nodule	4 (8%)	5 (10%)	7 (14%)	2 (4%)	4 (8%)
Cyst					1 (2%)
Degeneration, Fatty		1 (2%)			1 (2%)
Hyperplasia, Focal	5 (10%)	7 (14%)	5 (10%)	2 (4%)	1 (2%)
Hypertrophy, Focal	16 (32%)	20 (40%)	20 (40%)	14 (28%)	2 (4%)
Subcapsular, Hyperplasia	11 (22%)	7 (14%)	4 (8%)	7 (14%)	4 (8%)
Adrenal Medulla	(49)	(49)	(50)	(50)	(50)
Hyperplasia		2 (4%)	1 (2%)		
Islets, Pancreatic	(50)	(50)	(50)	(50)	(50)
Atrophy				1 (2%)	
Hyperplasia	12 (24%)	8 (16%)	12 (24%)	10 (20%)	3 (6%)
Parathyroid Gland	(43)	(48)	(47)	(46)	(48)
Cyst				4 (9%)	
Pituitary Gland	(48)	(50)	(48)	(49)	(49)
Pars Distalis, Cyst	4 (8%)	3 (6%)	2 (4%)	2 (4%)	
Pars Distalis, Hyperplasia, Focal	1 (2%)	2 (4%)	1 (2%)		
Rathke's Cleft, Dilatation					2 (4%)
Thyroid Gland	(49)	(50)	(50)	(49)	(50)
Follicle, Cyst				1 (2%)	
Follicle, Degeneration, Focal	13 (27%)	10 (20%)	11 (22%)	16 (33%)	6 (12%)
Follicular Cell, Hyperplasia		1 (2%)			
GENERAL BODY SYSTEM					
Tissue NOS	(1)	(1)	(1)	(1)	(0)
GENITAL SYSTEM					
Epididymis	(50)	(50)	(50)	(50)	(50)
Granuloma Sperm		2 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Inflammation, Chronic Spermatocoele		1 (2%)		1 (2%)	
Penis	(1)	(0)	(0)	(1)	(0)
Cyst				1 (100%)	
Preputial Gland	(49)	(49)	(50)	(50)	(50)
Cyst	12 (24%)	15 (31%)	7 (14%)	17 (34%)	3 (6%)
Inflammation, Chronic	13 (27%)	11 (22%)	10 (20%)	10 (20%)	5 (10%)
Prostate	(49)	(50)	(50)	(50)	(50)
Infiltration Cellular, Lymphocyte			1 (2%)		
Seminal Vesicle	(50)	(50)	(50)	(50)	(50)
Testes	(50)	(50)	(50)	(50)	(50)
Angiectasis		1 (2%)			
Germinal Epithelium, Atrophy		4 (8%)	2 (4%)	1 (2%)	
Interstitial Cell, Hyperplasia			1 (2%)		

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)	(50)
Hyperplasia	23 (46%)	25 (50%)	23 (46%)	21 (42%)	7 (14%)
Lymph Node	(3)	(0)	(1)	(1)	(0)
Lymph Node, Mandibular	(47)	(49)	(46)	(47)	(44)
Atrophy	1 (2%)	1 (2%)	1 (2%)		
Hemorrhage				1 (2%)	
Hyperplasia, Lymphoid	5 (11%)	1 (2%)	9 (20%)	5 (11%)	1 (2%)
Infiltration Cellular, Plasma Cell	1 (2%)				
Pigmentation		2 (4%)		1 (2%)	
Lymph Node, Mesenteric	(49)	(48)	(47)	(47)	(50)
Angiectasis	1 (2%)	2 (4%)	3 (6%)		
Atrophy	1 (2%)	1 (2%)	1 (2%)	3 (6%)	
Ectasia		1 (2%)		1 (2%)	
Hematopoietic Cell Proliferation	2 (4%)	2 (4%)		2 (4%)	
Hemorrhage	6 (12%)	4 (8%)	6 (13%)	2 (4%)	1 (2%)
Hyperplasia, Lymphoid	2 (4%)	5 (10%)	4 (9%)	5 (11%)	3 (6%)
Infiltration Cellular, Plasma Cell				1 (2%)	
Pigmentation		1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Spleen	(50)	(50)	(50)	(49)	(50)
Accessory Spleen		1 (2%)			
Angiectasis		1 (2%)			
Hematopoietic Cell Proliferation	20 (40%)	26 (52%)	24 (48%)	25 (51%)	9 (18%)
Pigmentation					1 (2%)
Lymphoid Follicle, Atrophy	2 (4%)	1 (2%)	3 (6%)	1 (2%)	
Lymphoid Follicle, Hyperplasia	1 (2%)	5 (10%)	5 (10%)	3 (6%)	1 (2%)
Thymus	(44)	(43)	(44)	(40)	(49)
Atrophy	3 (7%)	8 (19%)	4 (9%)	6 (15%)	2 (4%)
Cyst	1 (2%)	2 (5%)	1 (2%)	4 (10%)	
Hyperplasia, Lymphoid	1 (2%)	1 (2%)		1 (3%)	

INTEGUMENTARY SYSTEM

Skin	(50)	(50)	(50)	(50)	(50)
Cyst Epithelial Inclusion		2 (4%)			
Edema		1 (2%)	1 (2%)	2 (4%)	
Fibrosis			1 (2%)		
Inflammation, Chronic			1 (2%)		
Ulcer		2 (4%)		2 (4%)	
Epidermis, Hyperplasia			2 (4%)	1 (2%)	

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(49)	(50)
Hyperostosis	1 (2%)	1 (2%)			
Cranium, Osteopetrosis	1 (2%)	1 (2%)		2 (4%)	
Skeletal Muscle	(2)	(1)	(3)	(1)	(0)

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)	(50)
Necrosis				1 (2%)	
Pigmentation					1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
------------------	---------	---------	---------	----------	----------

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)	(50)
Foreign Body			1 (2%)		1 (2%)
Hemorrhage	2 (4%)	1 (2%)	1 (2%)		5 (10%)
Infiltration Cellular, Histiocyte		1 (2%)	1 (2%)	1 (2%)	
Inflammation, Chronic Active		1 (2%)			
Metaplasia, Osseous		1 (2%)	1 (2%)		1 (2%)
Thrombosis				2 (4%)	
Alveolar Epithelium, Hyperplasia	3 (6%)	1 (2%)	5 (10%)	4 (8%)	
Nose	(50)	(50)	(50)	(50)	(50)
Foreign Body		2 (4%)	1 (2%)	2 (4%)	
Inflammation, Chronic	5 (10%)	3 (6%)	4 (8%)	3 (6%)	2 (4%)
Respiratory Epithelium, Hyperplasia	1 (2%)				

SPECIAL SENSES SYSTEM

Eye	(50)	(50)	(50)	(50)	(50)
Atrophy	1 (2%)				
Cataract		1 (2%)			
Inflammation, Chronic		3 (6%)	2 (4%)		1 (2%)
Cornea, Hyperplasia		2 (4%)	1 (2%)		
Cornea, Ulcer					1 (2%)
Harderian Gland	(50)	(50)	(50)	(50)	(49)
Atrophy				1 (2%)	
Hyperplasia, Focal	1 (2%)	4 (8%)		2 (4%)	

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)	(50)
Cyst	11 (22%)	15 (30%)	9 (18%)	9 (18%)	1 (2%)
Hydronephrosis		1 (2%)			1 (2%)
Infarct	2 (4%)	3 (6%)	6 (12%)	5 (10%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Infiltration Cellular, Lymphocyte	1 (2%)	6 (12%)	5 (10%)	5 (10%)	1 (2%)
Metaplasia, Osseous	2 (4%)		5 (10%)	6 (12%)	1 (2%)
Necrosis			1 (2%)		
Nephropathy	40 (80%)	41 (82%)	38 (76%)	38 (76%)	16 (32%)
Artery, Inflammation, Chronic Active				1 (2%)	
Papilla, Necrosis					1 (2%)
Renal Tubule, Dilatation, Focal					1 (2%)
Renal Tubule, Hyperplasia					1 (2%)
Renal Tubule, Pigmentation	1 (2%)	3 (6%)		1 (2%)	
Urethra	(0)	(1)	(0)	(0)	(0)
Hemorrhage		1 (100%)			
Inflammation, Acute		1 (100%)			
Urinary Bladder	(50)	(50)	(50)	(50)	(50)
Dilatation		1 (2%)		1 (2%)	
Infiltration Cellular, Lymphocyte	2 (4%)				
Transitional Epithelium, Hyperplasia					1 (2%)

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
--------------------	---------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	50	50	50	50	50
Early Deaths					
Accidentally Killed	2				1
Dosing Accident		6			4
Moribund Sacrifice	4	4	2	3	8
Natural Death	7	6	8	6	37
Survivors					
Natural Death			1		
Terminal Sacrifice	37	33	39	41	
Animals Examined Microscopically	50	49	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(48)	(49)	(50)	(50)
Inflammation, Acute		6 (13%)			4 (8%)
Ulcer		4 (8%)			2 (4%)
Submucosa, Edema			1 (2%)		1 (2%)
Gallbladder	(43)	(39)	(43)	(46)	(46)
Inflammation, Acute	1 (2%)				
Pigmentation				2 (4%)	
Epithelium, Cytoplasmic Alteration	1 (2%)				
Intestine Large, Cecum	(48)	(46)	(46)	(49)	(49)
Edema				2 (4%)	
Intestine Small, Duodenum	(46)	(44)	(45)	(46)	(48)
Diverticulum				1 (2%)	
Intestine Small, Ileum	(48)	(47)	(45)	(49)	(48)
Epithelium, Hyperplasia				1 (2%)	
Intestine Small, Jejunum	(47)	(47)	(45)	(48)	(47)
Hyperplasia, Lymphoid	1 (2%)			1 (2%)	
Epithelium, Hyperplasia	1 (2%)				
Liver	(50)	(49)	(49)	(50)	(50)
Angiectasis	1 (2%)		1 (2%)		
Basophilic Focus	1 (2%)	2 (4%)		4 (8%)	
Clear Cell Focus	3 (6%)	2 (4%)	4 (8%)	2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Cyst	1 (2%)				
Eosinophilic Focus	3 (6%)	3 (6%)	3 (6%)	4 (8%)	
Hematopoietic Cell Proliferation	3 (6%)	3 (6%)	3 (6%)	2 (4%)	
Infiltration Cellular, Lymphocyte	2 (4%)	1 (2%)		4 (8%)	
Inflammation, Chronic Active	4 (8%)	3 (6%)	2 (4%)	7 (14%)	
Mixed Cell Focus	1 (2%)	5 (10%)		5 (10%)	
Necrosis, Focal	2 (4%)	6 (12%)	3 (6%)		2 (4%)
Necrosis, Diffuse		1 (2%)		1 (2%)	
Tension Lipidosis	1 (2%)	1 (2%)	2 (4%)	1 (2%)	
Centrilobular, Necrosis		1 (2%)	2 (4%)		
Hepatocyte, Hyperplasia, Focal			1 (2%)		
Hepatocyte, Vacuolization Cytoplasmic	7 (14%)	3 (6%)	2 (4%)	2 (4%)	
Kupffer Cell, Hyperplasia	2 (4%)	1 (2%)	1 (2%)	1 (2%)	
Mesentery	(10)	(6)	(5)	(6)	(0)
Necrosis	1 (10%)				
Fat, Necrosis	8 (80%)	6 (100%)	3 (60%)	6 (100%)	
Pancreas	(48)	(49)	(48)	(50)	(50)
Atrophy	2 (4%)	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Basophilic Focus	1 (2%)	1 (2%)	1 (2%)		
Cyst	1 (2%)		2 (4%)	3 (6%)	
Infiltration Cellular, Lymphocyte	3 (6%)		1 (2%)	1 (2%)	
Acinus, Cytoplasmic Alteration	2 (4%)		1 (2%)		
Salivary Glands	(49)	(48)	(49)	(50)	(50)
Infiltration Cellular, Lymphocyte	11 (22%)	13 (27%)	19 (39%)	13 (26%)	
Stomach, Forestomach	(50)	(49)	(48)	(50)	(50)
Diverticulum		1 (2%)	1 (2%)		
Erosion				1 (2%)	
Inflammation, Chronic			1 (2%)		
Epithelium, Hyperplasia			1 (2%)	2 (4%)	1 (2%)
Stomach, Glandular	(48)	(49)	(47)	(48)	(50)
Cyst	2 (4%)	1 (2%)	2 (4%)	2 (4%)	
Epithelium, Cytoplasmic Alteration				1 (2%)	
Epithelium, Hyperplasia	1 (2%)			1 (2%)	
Tongue	(0)	(0)	(0)	(0)	(1)
Cyst					1 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
CARDIOVASCULAR SYSTEM					
Heart	(50)	(49)	(50)	(50)	(50)
Cardiomyopathy		1 (2%)			
Inflammation, Acute		2 (4%)			
Mineralization	1 (2%)	2 (4%)	1 (2%)	1 (2%)	
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(49)	(49)	(50)	(50)
Accessory Adrenal Cortical Nodule	7 (14%)	5 (10%)	6 (12%)	9 (18%)	3 (6%)
Amyloid Deposition				1 (2%)	
Degeneration, Fatty	1 (2%)			1 (2%)	
Hyperplasia, Focal	2 (4%)	1 (2%)	1 (2%)		
Hypertrophy, Focal			1 (2%)	2 (4%)	
Capsule, Hyperplasia	1 (2%)	5 (10%)		4 (8%)	
Subcapsular, Cyst					1 (2%)
Subcapsular, Hyperplasia, Focal				1 (2%)	
Adrenal Medulla	(50)	(47)	(46)	(48)	(49)
Hyperplasia	1 (2%)	1 (2%)		1 (2%)	
Islets, Pancreatic	(48)	(49)	(48)	(50)	(50)
Cyst		1 (2%)			
Hyperplasia	1 (2%)		2 (4%)	4 (8%)	
Parathyroid Gland	(45)	(42)	(46)	(47)	(49)
Cyst	2 (4%)		1 (2%)		4 (8%)
Hyperplasia			1 (2%)		
Pituitary Gland	(49)	(48)	(48)	(49)	(47)
Pars Distalis, Cyst	3 (6%)	2 (4%)		3 (6%)	
Pars Distalis, Cytoplasmic Alteration, Focal	1 (2%)				
Pars Distalis, Hemorrhage				1 (2%)	
Pars Distalis, Hyperplasia, Focal	9 (18%)	4 (8%)	7 (15%)	4 (8%)	
Rathke's Cleft, Dilatation					1 (2%)
Thyroid Gland	(50)	(48)	(48)	(49)	(49)
Artery, Inflammation, Chronic Active		1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Follicle, Cyst	1 (2%)	2 (4%)			
Follicle, Degeneration, Focal Follicular Cell, Hyperplasia	28 (56%)	15 (31%)	28 (58%)	23 (47%) 3 (6%)	2 (4%)
GENERAL BODY SYSTEM					
Tissue NOS	(1)	(0)	(0)	(0)	(0)
GENITAL SYSTEM					
Clitoral Gland	(48)	(46)	(48)	(49)	(47)
Ovary	(48)	(47)	(49)	(48)	(50)
Amyloid Deposition				1 (2%)	
Angiectasis	1 (2%)	1 (2%)	2 (4%)	4 (8%)	
Cyst	15 (31%)	14 (30%)	14 (29%)	14 (29%)	2 (4%)
Hemorrhage	7 (15%)	5 (11%)	13 (27%)	10 (21%)	
Inflammation, Granulomatous		1 (2%)			
Mineralization		1 (2%)			
Pigmentation			2 (4%)		
Thrombosis	1 (2%)		1 (2%)		
Granulosa Cell, Hyperplasia		1 (2%)			
Uterus	(50)	(49)	(50)	(50)	(50)
Amyloid Deposition				1 (2%)	
Angiectasis	1 (2%)	1 (2%)	2 (4%)	4 (8%)	
Infiltration Cellular, Histiocyte	1 (2%)				
Inflammation, Suppurative	1 (2%)				
Inflammation, Acute		1 (2%)		1 (2%)	
Necrosis				1 (2%)	
Pigmentation	1 (2%)				
Thrombosis	1 (2%)	1 (2%)	1 (2%)	1 (2%)	
Endometrium, Hyperplasia, Cystic	39 (78%)	26 (53%)	34 (68%)	35 (70%)	15 (30%)
Myometrium, Hypertrophy		1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
HEMATOPOIETIC SYSTEM					
Bone Marrow	(50)	(49)	(49)	(50)	(50)
Angiectasis		1 (2%)			
Hyperplasia	19 (38%)	20 (41%)	13 (27%)	16 (32%)	5 (10%)
Myelofibrosis		1 (2%)			
Lymph Node	(6)	(3)	(3)	(1)	(0)
Bronchial, Atrophy		1 (33%)			
Bronchial, Pigmentation		1 (33%)			
Iliac, Ectasia	1 (17%)				
Iliac, Hematopoietic Cell Proliferation	1 (17%)				
Mediastinal, Atrophy		1 (33%)			
Mediastinal, Ectasia	1 (17%)				
Mediastinal, Pigmentation		1 (33%)			
Lymph Node, Mandibular	(48)	(46)	(45)	(48)	(49)
Atrophy	1 (2%)				
Hematopoietic Cell Proliferation	2 (4%)		1 (2%)		1 (2%)
Hyperplasia, Lymphoid	9 (19%)	6 (13%)	7 (16%)	2 (4%)	3 (6%)
Infiltration Cellular, Histiocyte				1 (2%)	
Pigmentation	4 (8%)	3 (7%)	4 (9%)	3 (6%)	
Lymph Node, Mesenteric	(46)	(49)	(46)	(48)	(47)
Atrophy		2 (4%)	1 (2%)	1 (2%)	1 (2%)
Ectasia	1 (2%)			2 (4%)	
Hematopoietic Cell Proliferation			1 (2%)	1 (2%)	
Hemorrhage	2 (4%)	4 (8%)	1 (2%)	4 (8%)	
Hyperplasia, Lymphoid	6 (13%)	6 (12%)	2 (4%)	7 (15%)	
Infiltration Cellular, Histiocyte				1 (2%)	
Necrosis		1 (2%)			
Pigmentation	1 (2%)			1 (2%)	
Spleen	(50)	(49)	(48)	(50)	(50)
Amyloid Deposition	1 (2%)				
Atrophy				1 (2%)	
Hematopoietic Cell Proliferation	33 (66%)	39 (80%)	36 (75%)	37 (74%)	5 (10%)
Pigmentation	1 (2%)			1 (2%)	1 (2%)
Lymphoid Follicle, Atrophy				1 (2%)	
Lymphoid Follicle, Hyperplasia	12 (24%)	14 (29%)	12 (25%)	17 (34%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Thymus	(46)	(45)	(46)	(48)	(49)
Atrophy	4 (9%)	8 (18%)	5 (11%)	6 (13%)	3 (6%)
Cyst		1 (2%)			
Hemorrhage	1 (2%)	1 (2%)			
Hyperplasia, Lymphoid	6 (13%)	1 (2%)	2 (4%)	4 (8%)	1 (2%)
Inflammation, Chronic Active		3 (7%)			3 (6%)
INTEGUMENTARY SYSTEM					
Mammary Gland	(50)	(49)	(50)	(50)	(50)
Hyperplasia	5 (10%)	5 (10%)	3 (6%)	6 (12%)	
Skin	(50)	(49)	(50)	(50)	(50)
Cyst Epithelial Inclusion				1 (2%)	
Edema		1 (2%)		1 (2%)	
Hemorrhage					1 (2%)
Inflammation, Chronic Active		1 (2%)			
Ulcer	2 (4%)	1 (2%)			
Subcutaneous Tissue, Inflammation, Chronic Active		1 (2%)			
MUSCULOSKELETAL SYSTEM					
Bone	(50)	(49)	(50)	(50)	(50)
Fibrosis	1 (2%)	2 (4%)	1 (2%)	3 (6%)	
Fracture	1 (2%)		2 (4%)		
Femur, Hyperostosis	1 (2%)				
Skeletal Muscle	(3)	(2)	(0)	(0)	(0)
NERVOUS SYSTEM					
Brain	(50)	(49)	(50)	(50)	(50)
Compression	1 (2%)			1 (2%)	
Cyst Epithelial Inclusion	1 (2%)				
Hemorrhage				1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Necrosis Artery, Meninges, Inflammation, Chronic Active	1 (2%)	1 (2%)		1 (2%)	

RESPIRATORY SYSTEM

Lung	(50)	(49)	(50)	(50)	(50)
Fibrosis		1 (2%)			
Foreign Body		8 (16%)			5 (10%)
Hemorrhage	2 (4%)		1 (2%)	7 (14%)	6 (12%)
Infiltration Cellular, Histiocyte			1 (2%)		
Infiltration Cellular, Lymphocyte	2 (4%)		2 (4%)	4 (8%)	
Inflammation, Suppurative		1 (2%)			
Inflammation, Granulomatous		1 (2%)			
Inflammation, Acute		4 (8%)	1 (2%)		
Inflammation, Chronic	1 (2%)				1 (2%)
Inflammation, Chronic Active		2 (4%)			1 (2%)
Metaplasia, Osseous			1 (2%)		
Thrombosis	1 (2%)			1 (2%)	
Alveolar Epithelium, Hyperplasia	1 (2%)	1 (2%)	1 (2%)		
Arteriole, Hypertrophy					1 (2%)
Nose	(50)	(49)	(50)	(50)	(50)
Foreign Body	1 (2%)	4 (8%)			
Inflammation, Chronic	2 (4%)	4 (8%)	2 (4%)		
Pleura	(0)	(0)	(0)	(0)	(4)
Inflammation, Acute					4 (100%)
Trachea	(50)	(49)	(50)	(50)	(50)
Inflammation, Chronic Active					1 (2%)

SPECIAL SENSES SYSTEM

Eye	(50)	(49)	(50)	(50)	(50)
Atrophy		1 (2%)		1 (2%)	
Cataract			2 (4%)		
Inflammation, Chronic	1 (2%)	2 (4%)	2 (4%)	2 (4%)	
Cornea, Hyperplasia		1 (2%)	2 (4%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 99037 - 06
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)
 alpha/beta Thujone mixture
 CAS Number: THUJONEMIXAB

Date Report Requested: 08/11/2010
 Time Report Requested: 13:12:57
 First Dose M/F: 06/30/03 / 06/30/03
 Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG	25 MG/KG
Harderian Gland	(50)	(49)	(50)	(49)	(50)
Cyst			1 (2%)		
Hyperplasia, Focal	1 (2%)	1 (2%)	1 (2%)	1 (2%)	
Infiltration Cellular, Lymphocyte			1 (2%)		
URINARY SYSTEM					
Kidney	(50)	(49)	(49)	(50)	(50)
Amyloid Deposition				1 (2%)	
Cyst	3 (6%)	3 (6%)		1 (2%)	
Glomerulosclerosis		1 (2%)			
Infarct	2 (4%)	5 (10%)	6 (12%)	1 (2%)	
Infiltration Cellular, Lymphocyte	3 (6%)	9 (18%)	5 (10%)	5 (10%)	
Inflammation, Chronic	1 (2%)				
Metaplasia, Osseous	1 (2%)	1 (2%)	2 (4%)	3 (6%)	
Mineralization				1 (2%)	
Nephropathy	11 (22%)	11 (22%)	5 (10%)	7 (14%)	3 (6%)
Renal Tubule, Accumulation, Hyaline Droplet	1 (2%)	2 (4%)	1 (2%)	2 (4%)	
Renal Tubule, Cytoplasmic Alteration			1 (2%)		
Renal Tubule, Pigmentation	1 (2%)		2 (4%)		
Urinary Bladder	(50)	(49)	(49)	(50)	(50)
Infiltration Cellular, Lymphocyte	2 (4%)	1 (2%)	2 (4%)	4 (8%)	

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion